Gastroesophageal reflux after endoscopic injection sclerotherapy.
The effect of sclerotherapy of esophageal varices on the gastroesophageal reflux was studied. Gastroesophageal reflux was monitored by a 24-h pH-monitoring catheter introduced into the distal esophagus. The results of pH monitoring of 16 patients who underwent sclerotherapy were compared with those of 21 patients with untreated varices. Seven of the 16 treated patients showed high occurrence rates of gastroesophageal reflux comparable to those observed in cases with severe reflux esophagitis. In the untreated group, only one patient showed pathological reflux (there was a significant difference between treated and untreated groups; p less than 0.01). When the level of reflux was compared with factors that might influence sclerotherapy-induced gastroesophageal reflux, there was a positive correlation between the magnitude of reflux and amount of sclerosant injected paravariceally in the submucosal tissue (p less than 0.05). The results indicate that the paravariceal injection of sclerosant for the treatment of esophageal varix may cause pathological gastroesophageal reflux after sclerotherapy is completed.
Kinoshita
Y
Y
Department of Internal Medicine, Miki City Hospital, Japan.
Kitajima
N
N
Itoh
T
T
Ishido
S
S
Nishiyama
K
K
Kawanami
C
C
Kishi
K
K
Inatome
T
T
Fukuzaki
H
H
Chiba
T
T
D000704:Analysis of Variance; D004932:Esophageal and Gastric Varices / Q000503:physiopathology / Q000628:therapy*; D004947:Esophagus / Q000503:physiopathology*; D005764:Gastroesophageal Reflux / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008875:Middle Aged; D008991:Monitoring, Physiologic; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage; D012597:Sclerosing Solutions / Q000008:administration & dosage; D015911:Sclerotherapy / Q000009:adverse effects*
D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols